Trial site
Azienda Ulss 3 Serenissima
- 17running trials
- 9closed trials
The trials here
What the 26 trials at this site are about, from their registry records.
- Conditions
- Ovarian cancer4 trials
- Diffuse large B-cell lymphoma3 trials
- Acute lymphoblastic leukaemia2 trials
- Acute myeloid leukaemia2 trials
- Atrial fibrillation2 trials
- Chronic lymphocytic leukaemia2 trials
- Endometrial cancer2 trials
- Hodgkin lymphoma2 trials
- Lung cancer2 trials
- Coronary artery disease1 trial
- Deep vein thrombosis and pulmonary embolism1 trial
- Follicular lymphoma1 trial
- and 6 more
- Phase
- Phase 320 trials
- Phase 26 trials
- Status
- Completed9 trials
- Active, not recruiting8 trials
- Not yet recruiting5 trials
- Recruiting4 trials
- Lead sponsor
- Regeneron Pharmaceuticals2 trials
- AbbVie1 trial
- Acerta Pharma BV1 trial
- Acesion Pharma1 trial
- Amgen1 trial
- and 20 more
Running trials
Not yet recruiting
Recruiting
Recruiting
Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation
Recruiting
Recruiting
Recruiting
Recruiting
Active, not recruiting
Not yet recruiting
Active, not recruiting
Recruiting
Active, not recruiting
Recruiting
Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)
Active, not recruiting
Active, not recruiting
Active, not recruiting
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Acute myeloid leukaemia1 recruiting
- Atrial fibrillation1 recruiting
- Deep vein thrombosis and pulmonary embolism1 recruiting
- Endometrial cancer1 recruiting
- Head and neck cancer1 recruiting
- Hodgkin lymphoma1 recruiting
- Obesity1 recruiting
- Ovarian cancer1 recruiting
- Peripheral artery disease1 recruiting
Closed trials
Active, not recruiting
Completed
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
Completed
Recruiting
Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy
Active, not recruiting
Completed
Completed
Completed
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
Completed
Site data: ClinicalTrials.govUpdated 18 Nov 2026